The FTC’s request for a nearly 25% increase in funding for fiscal 2025 was splashed with cold water May 15 in a U.S. House Appropriations subcommittee hearing. That’s “a dramatic increase in funding for an agency whose work continues to raise concerns among many members of Congress and the public,” Rep. David Joyce (R-Ohio), chair of the Subcommittee on Financial Services and General Government, said as he opened the hearing. Read More
Biopharma companies have announced additional layoffs and restructurings in the past few weeks, after more than 7,800 job cuts were reported by BioWorld this year through late April. Through mid-May, total layoffs in the biopharma sector have increased to 9,848. Read More
Alto Neuroscience Inc.’s start this spring of the phase II double-blind, single- and multiple-dose study to test the pharmacodynamics of ALTO-203 in major depressive disorder represents another stake planted in a notoriously difficult indication. But getting attention as well is the push by Los Altos, Calif.-based Alto in post-traumatic stress disorder (PTSD) with a separate compound. Read More
A non-traditional route for financing has been the path to success for Fibrobiologics Inc. In the newest BioWorld Insider podcast, CEO Pete O’Heeron offers insight into the company’s unusual path to a Nasdaq listing in January. Read More
Artificial intelligence recently roiled the regulatory world, but the U.S. Congress has yet to dive into the task of legislating on the concept. Barrett Tenbarge, general counsel for Sen. Bill Cassidy (R-La.) told an audience here in the nation’s capital that while the Senate is considering several legislative proposals, the desire to avoid legislation that will create as many problems as it solves suggest that legislative development “is a long-term process.” Read More
The recent cyberattack on Change Healthcare, a part of the Unitedhealth Group, crippled reimbursement claims processing for thousands of providers for several weeks and potentially exposed troves of patient data. Congressional committees are investigating the attack, its scope, and Unitedhealth’s response. Please take a few minutes to fill out this short survey to help BioWorld understand how your company is responding to these threats. You can click through to the questions here. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: 89bio, Alligator, Atyr, Equillium, Fortress, Genprex, Hutchmed, Immatics, Kodiak, Kura, Neumora, Novo, Pliant, Sumitomo. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Artbio, Bayer, Centogene, Chiesi, Enveric, Evotec, Fogpharma, Merck & Co., Mindbio, Nykode, Plaquetec, Tavros, Unravel, Vividion. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Brii, Dynavax, Mabwell, PTC, Sanofi, Verismo, Zai. Read More
